Search
Sulfacetamide
go.drugbank.com/drugs/DB00634ApprovedAn anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
Inbakicept
go.drugbank.com/drugs/DB16479Investigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. … Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses.
BB 21217
go.drugbank.com/drugs/DB17373InvestigationalBB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP
Aminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnAminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...
Becaplermin
go.drugbank.com/drugs/DB00102ApprovedInvestigationalBecaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).
Orphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.